Mar 6, 2019 6:05 am EST Cerecor Increases Previously Announced Bought Deal of Common Stock to $10 Million
Feb 19, 2019 8:27 am EST Cerecor Receives Fast Track Designation from FDA for CERC-801 for the Treatment of PGM1 Deficiency
Jan 28, 2019 6:30 am EST Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland
Jan 22, 2019 6:30 am EST FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-801 for the treatment of PGM1 Deficiency
Jan 16, 2019 6:30 am EST FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation
Oct 31, 2018 4:00 pm EDT Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation
Oct 30, 2018 4:00 pm EDT Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism
